mHealth Incentivized Adherence Plus Patient Navigation (MIAPP): protocol for a pilot randomized controlled trial to improve linkage and retention on buprenorphine for hospitalized patients with methamphetamine use and opioid use disorder

被引:0
作者
Bhatraju, Elenore P. [1 ]
Kennedy, Devin N. [1 ]
Gojic, Alexander J. [1 ]
Iles-Shih, Matthew [2 ]
Merrill, Joseph O. [1 ]
Samet, Jeffrey H. [3 ,4 ]
Hallgren, Kevin A. [2 ]
Tsui, Judith I. [1 ]
机构
[1] Univ Washington, Harborview Med Ctr, Dept Med, Div Gen Internal Med, Box 359780,325 9Th Ave, Seattle, WA 98104 USA
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA USA
[3] Boston Univ, Sect Gen Internal Med, Chobanian & Avedisian Sch Med, Dept Med,Clin Addict Res & Educ CARE Unit, Boston, MA USA
[4] Boston Med Ctr, Boston, MA USA
来源
ADDICTION SCIENCE & CLINICAL PRACTICE | 2025年 / 20卷 / 01期
关键词
Buprenorphine; Opioid related disorders; Mobile Health (mHealth); Video directly observed therapy; Methamphetamine use; DRUG; VALIDITY; THERAPY; PEOPLE;
D O I
10.1186/s13722-025-00538-1
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
BackgroundInitiation of buprenorphine for treatment of opioid use disorder (OUD) in acute care settings improves access and outcomes, however patients who use methamphetamine are less likely to link to ongoing treatment. We describe the intervention and design from a pilot randomized controlled trial of an intervention to increase linkage to and retention in outpatient buprenorphine services for patients with OUD and methamphetamine use who initiate buprenorphine in the hospital.MethodsThe study is a two-arm pilot randomized controlled trial (N = 40) comparing the mHealth Incentivized Adherence Plus Patient Navigation (MIAPP) intervention to treatment as usual. Development of the MIAPP intervention was guided by the information-motivation-behavioral skills model and combines financial rewards via mobile health-based adherence monitoring with the "human touch" of a patient navigator. Participants receive financial incentives for submitting videos of themselves taking buprenorphine via smartphone. The Patient Navigator reviews videos and provides treatment adherence coaching, care coordination and motivational enhancement. The intervention is introduced prior to hospital discharge and is offered for 30 days. The primary outcome is linkage to outpatient buprenorphine care within 30 days of hospital discharge. Secondary outcomes include retention on buprenorphine 90 days post discharge, hospital readmissions, and past 30-day methamphetamine use.DiscussionInterventions are needed to increase linkage and retention to outpatient buprenorphine among hospitalized patients with OUD, especially for people who co-use methamphetamine. We will examine the MIAPP intervention to improve buprenorphine adherence and linkage to outpatient treatment in a pilot randomized controlled trial which will provide valuable insights about research approaches for hospitalized patients with substance use disorder.Trial registration number: NCT06027814. Date of Initial Release: 08/30/2023. Protocol Version: 03/21/2024.DiscussionInterventions are needed to increase linkage and retention to outpatient buprenorphine among hospitalized patients with OUD, especially for people who co-use methamphetamine. We will examine the MIAPP intervention to improve buprenorphine adherence and linkage to outpatient treatment in a pilot randomized controlled trial which will provide valuable insights about research approaches for hospitalized patients with substance use disorder.Trial registration number: NCT06027814. Date of Initial Release: 08/30/2023. Protocol Version: 03/21/2024.
引用
收藏
页数:11
相关论文
共 54 条
  • [1] Ahmad FB., 2021, PROVISIONAL DRUG OVE
  • [2] [Anonymous], 2021, TIP 63: Medications for Opioid Use Disorder Internet
  • [3] Non-pharmacological interventions for methamphetamine use disorder: a systematic review
    AshaRani, P., V
    Hombali, Aditi
    Seow, Esmond
    Ong, Wei Jie
    Tan, Jit Hui
    Subramaniam, Mythily
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2020, 212
  • [4] Successful engagement in buprenorphine treatment among hospitalized patients with opioid use disorder and trauma
    Bhatraju, Elenore P.
    Ludwig-Barron, Natasha
    Takagi-Stewart, Julian
    Sandhu, Harveen K.
    Klein, Jared W.
    Tsui, Judith, I
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2020, 215
  • [5] Bhatraju EP, 2022, COLL PROBL DRUG DEP
  • [6] A Patient Navigation Intervention for Drug-Involved Former Prison Inmates
    Binswanger, Ingrid A.
    Whitley, Elizabeth
    Haffey, Paul-Ryan
    Mueller, Shane R.
    Min, Sung-Joon
    [J]. SUBSTANCE ABUSE, 2015, 36 (01) : 34 - 41
  • [7] Brooklyn JR, 1935
  • [8] Risk factors associated with infection of blood-borne virus among people who used methamphetamine
    Cai, Yilin
    Dai, Zheng
    Wen, Sijin
    Bhandari, Ruchi
    [J]. BMC INFECTIOUS DISEASES, 2020, 20 (01)
  • [9] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [10] Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments
    Chesney, MA
    Ickovics, JR
    Chambers, DB
    Gifford, AL
    Neidig, J
    Zwickl, B
    Wu, AW
    [J]. AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2000, 12 (03): : 255 - 266